GetTopicDetailResponse(id=761999e7564, topicName=非鱗非小細(xì)胞肺癌, introduction=非鱗非小細(xì)胞肺癌, content=null, image=null, comments=4, allHits=1201, url=https://h5.medsci.cn/topic?id=99775, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=4935, tagList=[TagDto(tagId=4935, tagName=非鱗非小細(xì)胞肺癌)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1940676, encodeId=37dc19406e673, content=<a href='/topic/show?id=761999e7564' target=_blank style='color:#2F92EE;'>#非鱗非小細(xì)胞肺癌#</a>, objectTitle=非鱗非小細(xì)胞肺癌EGFR陰性腦轉(zhuǎn)移的治療策略如何？CSCO二線治療推薦沒有免疫聯(lián)合化療的推薦, objectType=article, longId=294781, objectId=1a2d294e81fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a2d294e81fd, replyNumber=0, likeNumber=90, createdTime=2022-09-10, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a2d294e81fd, moduleTitle=非鱗非小細(xì)胞肺癌EGFR陰性腦轉(zhuǎn)移的治療策略如何？CSCO二線治療推薦沒有免疫聯(lián)合化療的推薦, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1a2d294e81fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940674, encodeId=83ce19406e40b, content=<a href='/topic/show?id=761999e7564' target=_blank style='color:#2F92EE;'>#非鱗非小細(xì)胞肺癌#</a>, objectTitle=患者招募：重組人源化抗PD-1單克隆抗體（HX008）聯(lián)合化療對(duì)比帕博利珠單抗聯(lián)合化療作為一線方案治療晚期或轉(zhuǎn)移性非鱗非小細(xì)胞肺癌（NSCLC）的II/III期臨床研究, objectType=article, longId=204948, objectId=3cf1204948c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cf1204948c8, replyNumber=0, likeNumber=121, createdTime=2021-10-26, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cf1204948c8, moduleTitle=患者招募：重組人源化抗PD-1單克隆抗體（HX008）聯(lián)合化療對(duì)比帕博利珠單抗聯(lián)合化療作為一線方案治療晚期或轉(zhuǎn)移性非鱗非小細(xì)胞肺癌（NSCLC）的II/III期臨床研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=3cf1204948c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940675, encodeId=508b19406e500, content=<a href='/topic/show?id=761999e7564' target=_blank style='color:#2F92EE;'>#非鱗非小細(xì)胞肺癌#</a>, objectTitle=Front Oncol：貝伐單抗或帕博利珠單抗聯(lián)合培美曲塞+鉑類化療一線治療驅(qū)動(dòng)基因陰性晚期非鱗非小細(xì)胞肺癌(NSCLC)的直接療效對(duì)比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=93, createdTime=2022-09-05, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：貝伐單抗或帕博利珠單抗聯(lián)合培美曲塞+鉑類化療一線治療驅(qū)動(dòng)基因陰性晚期非鱗非小細(xì)胞肺癌(NSCLC)的直接療效對(duì)比, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1940673, encodeId=aa3c19406e357, content=<a href='/topic/show?id=761999e7564' target=_blank style='color:#2F92EE;'>#非鱗非小細(xì)胞肺癌#</a>, objectTitle=帕博利珠單抗聯(lián)合化療一線治療非鱗非小細(xì)胞肺癌, objectType=article, longId=168266, objectId=244716826602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=244716826602, replyNumber=0, likeNumber=102, createdTime=2020-03-26, rootId=0, userName=gao_jian4217, userId=c66088, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=244716826602, moduleTitle=帕博利珠單抗聯(lián)合化療一線治療非鱗非小細(xì)胞肺癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=244716826602)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
